Found: 71
Select item for more details and to access through your institution.
Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
- Published in:
- JAMA Health Forum, 2023, v. 4, n. 1, p. e225218, doi. 10.1001/jamahealthforum.2022.5218
- By:
- Publication type:
- Article
Medicare Spending on Drugs With Accelerated Approval, 2015-2019.
- Published in:
- JAMA Health Forum, 2021, v. 2, n. 12, p. 1, doi. 10.1001/jamahealthforum.2021.3937
- By:
- Publication type:
- Article
Estimating Rebates and Other Discounts Received by Medicare Part D.
- Published in:
- JAMA Health Forum, 2021, v. 2, n. 6, p. 1, doi. 10.1001/jamahealthforum.2021.0626
- By:
- Publication type:
- Article
Medicaid Spending on Antiretrovirals From 2007 Through 2019.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 5, p. 833, doi. 10.1093/cid/ciac833
- By:
- Publication type:
- Article
Reply to Boucher et al.
- Published in:
- Clinical Infectious Diseases, 2021, v. 72, n. 9, p. e422, doi. 10.1093/cid/ciaa095
- By:
- Publication type:
- Article
Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis.
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 7, p. 1671, doi. 10.1093/cid/ciz1039
- By:
- Publication type:
- Article
National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 11, p. e2343285, doi. 10.1001/jamanetworkopen.2023.43285
- By:
- Publication type:
- Article
FDA Approval of Cardiac Implantable Electronic Devices via Original and Supplement Premarket Approval Pathways, 1979-2012.
- Published in:
- JAMA: Journal of the American Medical Association, 2014, v. 311, n. 4, p. 385, doi. 10.1001/jama.2013.284986
- By:
- Publication type:
- Article
Medicare Negotiation's Drug Reformulation Problem.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.
- Published in:
- Annals of Internal Medicine, 2024, v. 177, n. 6, p. 833, doi. 10.7326/M23-3212
- By:
- Publication type:
- Article
Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA.
- Published in:
- Pharmaceutical Medicine, 2024, v. 38, n. 4, p. 303, doi. 10.1007/s40290-024-00527-w
- By:
- Publication type:
- Article
Drug Prices, Rebates, and Discounts.
- Published in:
- 2020
- By:
- Publication type:
- Letter to the Editor
Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups.
- Published in:
- Arthritis & Rheumatology, 2023, v. 75, n. 8, p. 1325, doi. 10.1002/art.42520
- By:
- Publication type:
- Article
Pursuing Value‐Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug–Pricing Boards.
- Published in:
- Milbank Quarterly, 2021, v. 99, n. 4, p. 1162, doi. 10.1111/1468-0009.12533
- By:
- Publication type:
- Article
Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
- Published in:
- Milbank Quarterly, 2021, v. 99, n. 1, p. 240, doi. 10.1111/1468-0009.12507
- By:
- Publication type:
- Article
Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty
- Published in:
- PLoS ONE, 2013, v. 8, n. 5, p. 1, doi. 10.1371/journal.pone.0062709
- By:
- Publication type:
- Article
Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable.
- Published in:
- Journal of Law, Medicine & Ethics, 2024, v. 52, n. 1, p. 188, doi. 10.1017/jme.2024.56
- By:
- Publication type:
- Article
Addressing High Drug Prices by Reforming Pharmacy Benefit Managers.
- Published in:
- Journal of Law, Medicine & Ethics, 2023, v. 51, p. 46, doi. 10.1017/jme.2024.23
- By:
- Publication type:
- Article
Transferable Exclusivity Vouchers and Incentives for Antimicrobial Development in the European Union.
- Published in:
- Journal of Law, Medicine & Ethics, 2023, v. 51, n. 1, p. 213, doi. 10.1017/jme.2023.58
- By:
- Publication type:
- Article
State Spending Targets for Prescription Drugs.
- Published in:
- 2024
- By:
- Publication type:
- Opinion
Changes in Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programs.
- Published in:
- JAMA Health Forum, 2024, v. 5, n. 4, p. e240302, doi. 10.1001/jamahealthforum.2024.0302
- By:
- Publication type:
- Article
Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.
- Published in:
- JAMA Health Forum, 2024, v. 5, n. 3, p. e235429, doi. 10.1001/jamahealthforum.2023.5429
- By:
- Publication type:
- Article
Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021.
- Published in:
- JAMA Health Forum, 2023, v. 4, n. 3, p. e230217, doi. 10.1001/jamahealthforum.2023.0217
- By:
- Publication type:
- Article
Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis.
- Published in:
- JAMA Neurology, 2024, v. 81, n. 1, p. 85, doi. 10.1001/jamaneurol.2023.4514
- By:
- Publication type:
- Article
Misaligned Pharmacy Incentives in Value-Based Care.
- Published in:
- 2024
- By:
- Publication type:
- Opinion
State Coverage and Reimbursement of Antiobesity Medications in Medicaid.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 14, p. 1230, doi. 10.1001/jama.2024.3073
- By:
- Publication type:
- Article
Spending on Targeted Therapies for Duchenne Muscular Dystrophy.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, p. 1151, doi. 10.1001/jama.2024.2776
- By:
- Publication type:
- Article
Direct-to-Consumer Drug Company Pharmacies.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 12, p. 1003, doi. 10.1001/jama.2024.2911
- By:
- Publication type:
- Article
The Inflation Reduction Act and Access to High-Cost Cardiovascular Therapies.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 17, p. 1619, doi. 10.1001/jama.2023.19129
- By:
- Publication type:
- Article
Gauging the Value of Top-Selling Drugs in Medicare—Reply.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 7, p. 665, doi. 10.1001/jama.2023.10961
- By:
- Publication type:
- Article
Congress' Misguided Plan to Ban QALYs.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 24, p. 2125, doi. 10.1001/jama.2023.8695
- By:
- Publication type:
- Article
Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 18, p. 1607, doi. 10.1001/jama.2023.3079
- By:
- Publication type:
- Article
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 15, p. 1283, doi. 10.1001/jama.2023.4034
- By:
- Publication type:
- Article
Estimated Medicare Part B Savings From Inflationary Rebates.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 1, p. 89, doi. 10.1001/jama.2022.20189
- By:
- Publication type:
- Article
Recent Trends in Prescription Drug Launch Prices-Reply.
- Published in:
- JAMA: Journal of the American Medical Association, 2022, v. 328, n. 13, p. 1352, doi. 10.1001/jama.2022.13828
- By:
- Publication type:
- Article
New Reforms to Prescription Drug Pricing in the US: Opportunities and Challenges.
- Published in:
- JAMA: Journal of the American Medical Association, 2022, v. 328, n. 11, p. 1041, doi. 10.1001/jama.2022.15268
- By:
- Publication type:
- Article
Trends in Prescription Drug Launch Prices, 2008-2021.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Association of California's Prescription Drug Coupon Ban With Generic Drug Use.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Changes in Induced Medical and Procedural Abortion Rates in a Commercially Insured Population, 2018 to 2022: An Interrupted Time-Series Analysis.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 11, p. 1508, doi. 10.7326/M23-1609
- By:
- Publication type:
- Article
Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company.
- Published in:
- 2022
- By:
- Publication type:
- research
Direct-to-Consumer Generic Drugs: A Maverick Approach or Another Exposure of Market Failures?
- Published in:
- 2022
- By:
- Publication type:
- editorial
The AViKA (Adding Value in Knee Arthroplasty) postoperative care navigation trial: rationale and design features.
- Published in:
- BMC Musculoskeletal Disorders, 2013, v. 14, n. 1, p. 1, doi. 10.1186/1471-2474-14-290
- By:
- Publication type:
- Article
The AViKA (Adding Value in Knee Arthroplasty) postoperative care navigation trial: rationale and design features.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Market dynamics of authorized generics in Medicaid from 2014 to 2020.
- Published in:
- Health Services Research, 2023, v. 58, n. 4, p. 953, doi. 10.1111/1475-6773.14145
- By:
- Publication type:
- Article
Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies.
- Published in:
- JGIM: Journal of General Internal Medicine, 2024, v. 39, n. 12, p. 2187, doi. 10.1007/s11606-024-08623-y
- By:
- Publication type:
- Article
Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Federal Spending on Off-Patent Drugs That Lack Generic Competition.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Effect of Shared Electronic Health Records on Duplicate Imaging after Hospital Transfer.
- Published in:
- 2020
- By:
- Publication type:
- letter
Patient Out‐of‐Pocket Costs Following the Availability of Biosimilar Versions of Infliximab.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 113, n. 1, p. 90, doi. 10.1002/cpt.2763
- By:
- Publication type:
- Article
Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012–2018.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 2, p. 367, doi. 10.1002/cpt.1983
- By:
- Publication type:
- Article